e-Therapeutics plc Rating Reiterated by Panmure Gordon (ETX)
e-Therapeutics plc (LON:ETX)‘s stock had its “buy” rating reaffirmed by equities research analysts at Panmure Gordon in a research note issued to investors on Friday, AnalystRatings.Net reports. They currently have a GBX 70 ($1.12) price target on the stock. Panmure Gordon’s price target suggests a potential upside of 122.22% from the company’s current price.
e-Therapeutics plc (LON:ETX) opened at 31.50 on Friday. e-Therapeutics plc has a one year low of GBX 23.00 and a one year high of GBX 38.50. The stock has a 50-day moving average of GBX 34.91 and a 200-day moving average of GBX 32.39.
e-Therapeutics plc (LON:ETX) is a drug discovery and development company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.